Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS). Anadys announced that it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.

The investigation concerns, among other things, whether the consideration to be paid to ANDS shareholders is unfair, inadequate, and substantially below the fair or inherent value. Indeed, analysts have projected that the true inherent value of PPDI is at least $4 per share. The investigation further concerns whether the board of directors of ANDS may have breached their fiduciary duties by not acting in ANDS shareholders' best interests in connection with the sale process of ANDS. Indeed, each of Anadys' directors and executive officers has agreed to tender their shares in the offer.

If you own ANDS common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact
Tripp Levy
Tripp Levy PLLC
125 East 82 nd Street
9 th Floor
New York, New York
Toll Free: 877-772-3975

Email: contact@tripplevy.com

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.

If you liked this article you might like

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Anadys To Be Bought by Roche for $230M

Anadys To Be Bought by Roche for $230M

Hep C Drug Updates: Vertex and Anadys

Hep C Drug Updates: Vertex and Anadys